Gut microbiome structure and metabolic activity in inflammatory bowel disease.

Nat Microbiol 2019 02 10;4(2):293-305. Epub 2018 Dec 10.

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

The inflammatory bowel diseases (IBDs), which include Crohn's disease (CD) and ulcerative colitis (UC), are multifactorial chronic conditions of the gastrointestinal tract. While IBD has been associated with dramatic changes in the gut microbiota, changes in the gut metabolome-the molecular interface between host and microbiota-are less well understood. To address this gap, we performed untargeted metabolomic and shotgun metagenomic profiling of cross-sectional stool samples from discovery (n = 155) and validation (n = 65) cohorts of CD, UC and non-IBD control patients. Metabolomic and metagenomic profiles were broadly correlated with faecal calprotectin levels (a measure of gut inflammation). Across >8,000 measured metabolite features, we identified chemicals and chemical classes that were differentially abundant in IBD, including enrichments for sphingolipids and bile acids, and depletions for triacylglycerols and tetrapyrroles. While > 50% of differentially abundant metabolite features were uncharacterized, many could be assigned putative roles through metabolomic 'guilt by association' (covariation with known metabolites). Differentially abundant species and functions from the metagenomic profiles reflected adaptation to oxidative stress in the IBD gut, and were individually consistent with previous findings. Integrating these data, however, we identified 122 robust associations between differentially abundant species and well-characterized differentially abundant metabolites, indicating possible mechanistic relationships that are perturbed in IBD. Finally, we found that metabolome- and metagenome-based classifiers of IBD status were highly accurate and, like the vast majority of individual trends, generalized well to the independent validation cohort. Our findings thus provide an improved understanding of perturbations of the microbiome-metabolome interface in IBD, including identification of many potential diagnostic and therapeutic targets.

Download full-text PDF

Source
http://www.nature.com/articles/s41564-018-0306-4
Publisher Site
http://dx.doi.org/10.1038/s41564-018-0306-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342642PMC
February 2019
45 Reads

Publication Analysis

Top Keywords

differentially abundant
20
inflammatory bowel
8
ibd including
8
metabolite features
8
changes gut
8
abundant species
8
metagenomic profiles
8
ibd
6
gut
5
abundant
5
differentially
5
tetrapyrroles while > 50%
4
putative roles
4
while > 50% differentially
4
assigned putative
4
abundant metabolite
4
features uncharacterized
4
uncharacterized assigned
4
association' covariation
4
profiles reflected
4

References

(Supplied by CrossRef)

M Wlodarska et al.
Cell Host Microbe 2015

F Imhann et al.
Gut 2018

C Huttenhower et al.
Immunity 2014

XC Morgan et al.
Genome Biol. 2012

D Gevers et al.
Cell Host Microbe 2014

Y Haberman et al.
J. Clin. Invest. 2014

ER Lane et al.
J. Inflamm. Res. 2017

JM Blander et al.
Nat. Immunol. 2017

PC Dorrestein et al.
Immunity 2014

IH McHardy et al.
Microbiome 2013

GD Wu et al.
Nestle Nutr. Inst. Workshop Ser. 2014

Similar Publications